Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics Q3 revenue rises to $47.6 million; net loss narrows to $190.1 million

Positive Impact 3 of 5 earnings

Cytokinetics reported third quarter 2026 results, with total revenue of $47.6 million, up from $1.9 million a year earlier, driven by $44.5 million in MYQORZO net product revenue. The net loss narrowed to $190.1 million, or $1.37 per share, from $306.2 million, or $2.55 per share, a year earlier, and the company reaffirmed its full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million.

Key points

  • Total Q3 2026 revenue was $47.6 million, including $44.5 million of MYQORZO net product revenue and $3.1 million of collaboration revenue.
  • Net loss for Q3 2026 was $190.1 million, or $(1.37) per share, versus $306.2 million, or $(2.55) per share, in Q3 2025.
  • Cash, cash equivalents and investments were approximately $1.6 billion at September 30, 2026, compared with $1.7 billion at June 30, 2026.
  • Full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million was reaffirmed.

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:05 PM ET
Accession number0001193125-26-447198

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.